• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Open Forum Infect Dis . Association Between Hemagglutination Inhibition Antibody Titers and Protection Against Reverse-Transcription Polymerase Cha

tetano

Editor, Senior Moderator
Open Forum Infect Dis


. 2021 Sep 25;9(2):ofab477.
doi: 10.1093/ofid/ofab477. eCollection 2022 Feb.
Association Between Hemagglutination Inhibition Antibody Titers and Protection Against Reverse-Transcription Polymerase Chain Reaction-Confirmed Influenza Illness in Children 6-35 Months of Age: Statistical Evaluation of a Correlate of Protection


Jasur Danier[SUP] 1 [/SUP], Andrea Callegaro[SUP] 2 [/SUP], Jyoti Soni[SUP] 3 [/SUP], Alfoso Carmona[SUP] 4 [/SUP], Pope Kosalaraska[SUP] 5 [/SUP], Luis Rivera[SUP] 6 [/SUP], Damien Friel[SUP] 7 [/SUP], Wenji Pu[SUP] 1 [/SUP], Valerie Vantomme[SUP] 2 [/SUP], Ghassan Dbaibo[SUP] 8 [/SUP], Bruce L Innis[SUP] 9 [/SUP], Anne Schuind[SUP] 1 [/SUP], Khalequ Zaman[SUP] 10 [/SUP], Jerome Wilson[SUP] 1 [/SUP]



Affiliations
Free PMC article

Abstract

Background: Data from a randomized controlled efficacy trial of an inactivated quadrivalent influenza vaccine in children 6-35 months of age were used to determine whether hemagglutination inhibition (HI) antibody titer against A/H1N1 and A/H3N2 is a statistical correlate of protection (CoP) for the risk of reverse-transcription polymerase chain reaction (RT-PCR)-confirmed influenza associated with the corresponding strain.
Methods: The Prentice criteria were used to statistically validate strain-specific HI antibody titer as a CoP. The probability of protection was identified using the Dunning model corresponding to a prespecified probability of protection at an individual level. The group-level protective threshold was identified using the Siber approach, leading to unbiased predicted vaccine efficacy (VE). A case-cohort subsample was used for this exploratory analysis.
Results: Prentice criteria confirmed that HI titer is a statistical CoP for RT-PCR-confirmed influenza. The Dunning model predicted a probability of protection of 49.7% against A/H1N1 influenza and 54.7% against A/H3N2 influenza at an HI antibody titer of 1:40 for the corresponding strain. Higher titers of 1:320 were associated with >80% probability of protection. The Siber method predicted VE of 61.0% at a threshold of 1:80 for A/H1N1 and 46.6% at 1:113 for A/H3N2.
Conclusions: The study validated HI antibody titer as a statistical CoP, by demonstrating that HI titer is correlated with clinical protection against RT-PCR-confirmed influenza associated with the corresponding influenza strain and is predictive of VE in children 6-35 months of age.
Clinical trials registration: NCT01439360.

Keywords: HI antibodies; children; correlate of protection; influenza.
 
Back
Top Bottom